

References for the Hormones & Beyond 2020 Neal Rouzier Presentations

Section #1.a

Emergency Medicine News | November 2017. www.EM-News.com

Testosterone study finds differing disease links in men and woman. Publication.

Liu, X. et al (2019). Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: The henan rural cohort study. *Diabetes Metab Res Rev*. <http://doi.org/10.1002/dmrr.3133>.

Zeller, T. et al. (2018). Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women results from finrisk study. *Eur J Prev Cardiol*. (11):1133-1139. doi:1177/2047487318778346.

Missmer, S. A. et al. (2004). Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. *Journal of the National Cancer Institute*, 96 (24).

Kaaks, R. et al. (2005). Serum Sex Steroids in Premenopausal Women and breast cancer risk within the European Prospective Investigation in Cancer and Nutrition (EPIC). *J Natl Cancer Insti*. 18, 97(10): 755-65.

Pasanisi, B. F. et al. (2005). Serum Testosterone levels and breast cancer recurrence. *Int. J. Cancer*, 113 (3), 499-502.

Hofling, M. et al. (2007). Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. *Menopause: The Journal of the North American Menopause Society*, 14 (2) 1-8.

Gera, R. et al. (2018). Does transdermal testosterone increase the risk of developing breast cancer? A systematic review. *Anticancer Research*, 38:6615-6620
doi: 10.21873/anticancer.13028.

Pasqualini, J. R. et al. (2010). Hormone molecular biology and clinical investigation. *Hormone Molecular Biology and Clinical Investigation*, 2 (1), 177-190.

Dimitrakakis, C. et al. (2009). Androgens and breast. *Breast Cancer Research*, 11:212.
Doi:10.1186/bcr2413.

Dimitrakakis, C. et al. (2004). Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. *Menopause*, 11 (5), 531-535.

Somboonpom W. D. et al (2004). Testosterone effect on the breast: implications for testosterone therapy for women. *Endocr Rev*, 25 (3), 374-388.

Dimitrakakis, C. (2011). Androgens and breast cancer in men and women. *Endocrinol Metab Clin North AM*, 40 (3), 533-547.

Hogervorst, E. (2013). Effects of gonadal hormones on cognitive behavior in elderly men and women. *J Neuroendocrinol*, 25(11): 1182-95. doi: 10.1111.jne.12080.

High risk medication review based on recent prescription claims. Publication.

Lhemite, M. et al. (2008). Could transdermal estradiol +progesterone be a safer postmenopausal HRT? A Review. *Maturitas*, 60,(3-4), 185-201.

Aubert, C. E. (2017). Thyroid function tests in the reference range and fracture: Individual participant analysis of prospective cohorts. *J Clin Endocrinol Metab*, 102(8):2719-2728.

Arjola, B. et al. (2017). Association of thyroid function with life expectancy with and without cardiovascular disease. *JAMA Intern Med*. doi:10.1001.jamainternmed.2017.4836.

Khan, S. R. (2016). Thyroid function and cancer risk: The Rotterdam Study. *The Journal of Clinical Endocrinology & Metabolism*, Volume 101, Issue 12, 1, 5030-5036.

Mahmood, R. et al. (2014). Comparative study of alterations in Tri-iodothyronine (T-3) and Thyroxine (T4) hormone levels in breast and ovarian cancer. *Pak J Med Sci*, 30(6) doi:1012669/pjms.306.5294.

Zhang, V. et al. (2014). Thyroid hormones and mortality risk in euthyroid individuals: The Kangbuk Samsung Health Study. *J Clin Endocrinol Metab*, 99(7):2467-2476 doi: 10.1210/jc.2013-3.

Tomaszewski, M. et al. (2009). Association between lipid profile and circulating concentrations of estrogens in young men. *Atherosclerosis*, 203 (1), 257-262.

Chen, H. R. et al (2020). Estradiol is an independent risk factor for organic erectile dysfunction in eugonadal young men. *Asian Journal of Andrology* 22,1-6. doi: 10.4103/aja.aja_135_19; published online; 10 January 2020.

El-Sakka, A. (2013). Impact of the Association Between Elevated Oestradiol and Low Testosterone Levels on Erectile Dysfunction Severity. *Asian Journal of Andrology*, 15, 492-496; doi:10.1038/aja.2013.20; published online 6 May 2013

Zuniga, K. B. et al. (2019). The Association Between Elevated Serum Oestradiol levels and Clinically Significant Erectile Dysfunction in Men Presenting for Andrological Evaluation. <https://doi.org/10.1111/and.13345>.

Xu, Z. H. et al. (2019). Effect of estradiol on penile erection. *Transl Androl Urol.* 8(6):574-582.

Xu, X. H. et al. (2019). Effect of prolactin on penile erection: A cross-sectional study. *Asian J Androl*, 21(6):587-591. doi: 10.4103/aja.aja_22_19.

(2011). Hypogonadism as a risk factor for cardiovascular mortality in men: A meta-analytic study. *European Journal of Endocrinology*, 165 (5), pp.687-701.

(2018). Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. *JAMA Oncol.* 4(8):1059-1065. doi10.1001/jamaoncol.2018.0211

(2020). The impact of adjunctive metformin to progesterone for endometrial hyperplasia. <https://doi.org/10.1016/j.jogoh.2020.101863>.

(2002). Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. *Circulation*, 106:1646-1651 doi: 10.1161/01.CIR.0000030940.73167.4E.

(2012). Injectable contraceptives linked to increased breast cancer risk. <https://www.foxnews.com/health/2012/04/05injectable-contraceptives>.

Section #1.b:

(2016). How a Cell's Fuel Gauge Promotes Healthy Development. Salk Institute. ScienceDaily, April, 016. www.sciencedaily.com/releases/2016/04/160425192820.htm.

(2007). AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling. *Circ Res*, 100:328-341. doi:10.1161/RES.0000256090.42690.05.

(2007). Minireview: The AMPK-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy. *Endocrinology* 144[12]:5179-5183. doi10.1210/en.2003-0982.

(2016). Genetic “whodunit” for Cancer Gene Solved. Source: Salk Institute.

(2019). Genetic Analysis Reveals AMPK Is Required to Support Tumor Growth in Murine Kras-Dependent Lung Cancer Model. *Cell Metabolism* 29, 285-302 February 5, 2019 doi:10.1016/j.cmet.2018.10.005.

(2018). AMPK: The Energy-boosting, Hormone-balancing Benefits of AMPK. Jillian Levy, CHHC November 25, 2018.

(2006). AMP-Activated Protein Kinase – Development of the Energy Sensor Concept. *J Physiol* 574.1 pp7-15 doi:10.1113/jphysiol.2006.108944.

Metformin and Reduced Risk of Cancer in Diabetic Patients.
<http://bmj.com/cgi/doi/10.1136/bmj.38415.708634.F7>.

Section #2.a

(2016). Metformin is Associated with Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. *Medicine(Baltimore)*.95(7):e2749. doi: 10.1097/MD.0000000000002749.

(2016). Metformin and Prostate Cancer Mortality: A Meta-analysis. *Cancer Causes Control*, 27(1);105-13. doi 10.1007/s10552-015-0687-0.

(2012). Cancer Risk Associated with use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. *Oncologist*,17(6):813-22.
doi: 10.1634/theoncologist.2011-0462.

(2019). Diabetes Drugs in the Fight Against Alzheimer's Disease. *Ageing Res Rev*, 54:100936. doi: 10.1016/j.arr.2019.100936.

(2017). Metformin-A Future Therapy for Neurodegenerative Diseases: Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease. *Pharm Res*, 34(12):2614-2627. doi: 10.1007/s11095-017-2199-y.

(2016). Metformin may Protect Nondiabetic Breast Cancer Women from Metastasis. *Clin Exp Metastasis*, 33(4):339-57. doi:10.1007/s10585-016-9782-1.

(2002). Role of Insulin-like Growth Factor Binding Protein-3 in Breast Cancer Cell Growth. *Micro Res Tech*, 1:59 (1);12-22.

(2019). Metformin as an Adjuvant in Breast Cancer Treatment. *SAGE Open Med*. 16;7:2050312119865114. doi: 10.1177/2050312119865114.

(2012). Diabetes Increases Risk of All-cause and Cancer-Specific Mortality. *Diabetes Care*, Online before print [June 14, 2012].

(2018). Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes. *Cancer Epidemiol Biomarkers Prev*. 2018 Jun;27(6):627-635. doi: 10.1158/1055-9965.EPI-17-0936.

(2020). Metformin: Current Clinical Applications in Nondiabetic Patients with Cancer. *Ageing (Albany, NY)*, 12(4):3993-4009. doi: 10.18632/aging.102787.

(2013). Association of Metformin use with Cancer Incidence and Mortality: A Meta-analysis. *Cancer epidemiol*, 37(3):207-18. doi: 10.1016/j.canep.2012.12.009.

(2016). Abstract. DOI: 10.4158/ep151145.RAR 2016 AACE.

(2010). Metformin: Taking Away the Candy for Cancer? *European Journal of Cancer* Vol46, Issue 13, P2369-2380, September 01, 2010. doi: 10.1016/j.ejca.2010.06.012.

(2019). Comment and Response Metformin for Type 2 diabetes. *JAMA*, 322, 13.

(2016). Metformin Loaded Carbopol Gel for Lowering the Intra-abdominal Visceral Fat. *J Bioequiv Availab*. Volume 8(4): 149-152 (2016) – 143 doi: 10.4172/jbb.1000286.

Transdermal Metformin Gel.

(2020). Menopausal Hormone Therapy and Long-Term Breast Cancer Risk. *JAMA*, 324, (4).

(2020). Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality During Long-Term Follow-Up of the Women's Health Initiative Randomized Clinical Trials. *JAMA*, 324 (4), 369-380. doi:10.1001/jama.2020.9482

Section #2.b

(1996). Relative Weight, Weight Change, Height, and Breast Cancer Risk in Asian-American Women. *J Natl Cancer Inst*, 88:650-60.

(2016). Inflammation, Dysregulated Metabolism and Aromatase in Obesity and Breast Cancer. *Current Opinion in Pharmacology* Volume 31, Pages 90-96
doi: 10.1016/j.coph.2016.11.003.

(2005). Breast Cancer Risk in the WHI Study: The Problem of Obesity. *Maturitas*. 51(1):83-97.

(2019). Estrogen Alone Appears to Lower Breast Cancer Risk and Death Long Term in Patient Subgroups. Home>>News>>Conference Coverage>> San Antonio Breast Cancer Symposium (SABCS)>> SABCS 2019.

(2019). Long-Term Influence of Estrogen Plus Progestin and Estrogen Alone Use on Breast Cancer Incidence: The Women's Health Initiative Randomized Trials. San Antonio Breast Cancer Symposium December 10-14, 2019
<https://www.sabcs.org/2019-SABCS>.

Testosterone Increases the Expression and Phosphorylation of AMP Kinase α in Men with Hypogonadism and Type 2 Diabetes. *The Journal of Clinical Endocrinology and Metabolism*, dgz288, <https://doi.org/clinem/dgz288>.

(2014). The Role of AMP-Activated Protein Kinase in the Androgenic Potentiation of Cannabinoid-Induced Changes in Energy Homeostasis. *AM J Physiol Endocrinol Metab* 308: E482-E495. 2015 doi: 10.1152/ajpendo00421.2014.

(2016). Testosterone Stimulates Glucose Uptake and GLUT4 Translocation Through LKB1/AMPK Signaling in 3T3-L1 Adipocytes. *Endocrine*, 51(1):174-84. doi: 10.1007/s12020-015-0666-y.

(2013). The Effect of Statins on Testosterone in Men and Women, a Systematic Review and Meta-Analysis of Randomized Controlled Trials. *BMC Medicine*, 11:57 <http://www.biomedcentral.com/1741-7015/11/57>.

(2018). The Clinical Impact of Estrogen Loss on Cardiovascular Disease in Menopausal Females. *Med Res Arch*, 6 (2).

(2015). New Mechanisms of Metformin Action: Focusing on Mitochondria and the Gut. *J Diabetes Investig*, 6:600-609. doi: 10.1111/jdi.12328.

(2019). Recent Advances in the Understanding and Management of Polycystic Ovary Syndrome. F1000Research 2019, 8(F1000 Faculty Rev):565 Last updated: 29 APR 2019.

(2019). 'Aggressive' Breast Cancer Risk Elevated with Type 2 Diabetes. *Diabetes care*. doi:10.2337/de18-2146.

Resting Energy Expenditure in Obese Women with Primary Hypothyroidism and Appropriate Levothyroxine Replacement Therapy.

Section #3.a

(2009). Insulin, Insulin-like Growth Factor-1, and Risk of Breast Cancer in Postmenopausal Women. *J Natl Cancer Inst*, 101:48-60 Vol. 101, Issue 1 January 7, 2009.

(2012). Understanding Weight Gain at Menopause. *Climateric*, 15:419-429.

(2004). Serum Leptin Levels and Body Composition in Postmenopausal Women: Effects of Hormone Therapy. *Menopause*, 11(4):466-73.

(2014). Significant Role of Estrogen in Maintaining Cardiac Mitochondrial Functions. <https://doi.org/10.1016/j.jsbmb.2014.11.009>.

(2013). Long-term treatment of hypogonadal men. *Obesity*, Volume 21 Number 10 October 2013.

(2013). Actions of 17 β -Estradiol and Testosterone in the Mitochondria and their implications in Aging. *Aging Res Rev*, 12(4):907-17.
doi: 10.1016/j.arr.2013.09.001.

(2009). Testosterone Addition to Estrogen Therapy-Effects on Inflammatory Markers for Cardiovascular Disease. *Gynecol Endocrinol*. 25(12):823-7.
doi: 10.3109/09513590903056134.

(2019). The Anti-inflammatory Effects of Testosterone. *Journal of the Endocrine Society*, Vol. 3, Iss. 1 91-107 doi: 10.1210/js.2018-00186.

(2014). Testosterone and Weight Loss: The Evidence. *Curr Opin Endocrinol Diabetes Obes*, 21:313-322.

(2020). Clinical Associations of Thyroid Hormone Levels with the Risk of Atherosclerosis. *International Journal of Endocrinology Volume 2020*
doi: 10.1155/2020.2172781.

Section #3.b

(2015). Aromatase Overexpression in Dysfunctional Adipose Tissue Links Obesity to Postmenopausal Breast Cancer. *J Steroid Biochem Mol Biol*, 153:25-44
doi: 10.1016/j.jsbmb.2015.07.008.

(2018). Obesity and Breast Cancer – Role of Estrogens and the Molecular Underpinnings of Aromatase Regulation in Breast Adipose Tissue. *Mol Cell Endocrinol*, 5:466:15-30. doi: 10.1016/j.mce.2017.09.014.

(2016). Inflammation, Dysregulated Metabolism and Aromatase in Obesity and Breast Cancer. *Curr Opin Pharmacol*, 31:90-96. doi 10.1016/j.coph.2016.11.003.

(2019). Estrogens and Breast Cancer: Mechanisms Involved in Obesity-Related Development, Growth and Progression. *J Steroid Biochem Mol Biol*, 189:161-170 doi: 10.1016/j.jsbmb.2019.03.002.

(2003). Sources of Estrogen and Their Importance. *Journal of Steroid Biochemistry and Molecular Biology* 86, 225-230.

(2011). Potential Utility of Natural Products as Regulators of Breast Cancer-Associated Aromatase Promoters. *Reproductive Biology and Endocrinology*, 9;91.

(2013). Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women. *Recent Patents on Anti-Cancer Drug Discovery*, 8, 154-167.

Section #4.a

(2020). Medications for Primary Prevention of Breast Cancer. *JAMA*, Volume 324, Number 3.

(2019). USPSTF Recommends Preventive Drugs for Women at High Breast Cancer Risk. USPSTF. *JAMA*.2019;doi:10.1001/jama.2019.11885.

(2018). Potential Mechanisms of Age Acceleration Caused by Estrogen Deprivation: Do Endocrine Therapies Carry the same Risks? *JNCI Cancer Spectr*, 10;2(3):pky035. doi: 10.1019/jncics/pky035.

(2002). Does Tamoxifen Prevent Breast Cancer? *The Journal of Family Practice*, Volume 50, No. 12 1023.

(2019). Causes of Death After Breast Cancer Diagnosis: A US Population-based Analysis. First Published: 16 December 2019 doi:10.1002/cncr.32648.

(2019). Heart Disease Biggest Killer Among Breast Cancer Survivors. www.Medscape.com. 9 Liam Davenport.

(2012). Aromatase Inhibitors and Mood Disturbances: A Case Study. *Palliat Support Care*,10(3): 225-227. doi 0.1017/S1478951512000636.

(2018). Cognitive Effects of Aromatase and Possible Role in Memory Disorder. *Front. Endocrinol* 9:610. doi. 10.3389/fendo.2018.00610.

(2015). Comparative Study on Individual Aromatase Inhibitors on Cardiovascular Safety Profile: A Network Meta-Analysis. *OncoTargets and Therapy*, 8 2721-2730.

(2013). Meta-Analysis of Breast Cancer Outcome and Toxicity in Adjuvant Trails of Aromatase Inhibitors in Postmenopausal Women. *The Breast* 22,121-129 doi: 10.1016/j.breast.2013.01.014.

(2019). Partner Status Moderates the Relationships Between Sexual Problems and Self-Efficacy for Managing Sexual Problems and Psychosocial Quality of Life for Postmenopausal Breast Cancer Survivors Taking Adjuvant Endocrine Therapy. *Menopause*. 26(8):823-832. doi:10.1097/GME.0000000000001337.

(2015). Molecular Mechanisms of Tamoxifen-Associated Endometrial Cancer (Review). *Oncology Letters* 9: 1495-1501. 2015 doi: 10.3892/ol.2015.2962.

(2016). Aromatase: Contributions to Physiology and Disease in Women and Men. *Physiology* 31:258-269, 2016. doi:10.1152/physiol.00054.2015.

(2007). Aromatase Inhibitor-Associated Arthralgia Syndrome. *Breast*. 16(3), 223-34.

Section #4.b

(2008). Menopausal Hormone Therapy and Breast Cancer: What is the Evidence From Randomized Trials? *Climacteric*. 21(6): 521-528. doi:10.1080/13697137.2018.1514008.

(2006). The Effect of Medroxyprogesterone Acetate on Estrogen-Dependent Risks and Benefits. *Gynecol Endocrinol*. 22(6):303-17.

(2006). The Effect of Medroxyprogesterone Acetate on Estrogen-Dependent Risks and Benefits-An Attempt to Interpret the Women's Health Initiative Results. *Gynecol Endocrinol*, 22(6):303-17.

(2014). Menopausal Hormone Therapy and Breast Cancer. *Journal of Steroid Biochemistry & Molecular Biology* 1-12(2014) 52-61.

(2019). Long-Term Influence of Estrogen Plus Progestin and Estrogen Alone Use on Breast Cancer Incidence. Oral presentation at the San Antonio Breast Cancer Symposium; December 10-14, 2019 San Antonio, Texas.

(2019). HRT has 20-Year Impact on Breast Cancer Risks. MEDPAGE Today December 13, 2019.

(2019). Long-term Influence of Estrogen Plus Progestin and Estrogen Alone Use on Breast Cancer Incidence. <https://www.sabcs.org/2019-SABCS>.

(2018). Estrogen-alone therapy and Invasive Breast Cancer Incidence by Dose, Formulation and Route of Delivery. *Menopause*: Volume 25 – Issue 9 – p 985-991. doi: 10.1097/GME.0000000000001115.

(2013). Unopposed Estrogen and Combination Hormone Therapy Have Distinctly Different Effects on the Breast. *OBG Management* Vol. 25 No. 6.

(2012). Effect of Hormone Replacement Therapy on Cardiovascular Events in Recently Postmenopausal Women: Randomised Trial. *BMJ* 2012:345:e6409 doi: 10.1136/bmj.e6409.

(2009). Breast Cancer Risk in Postmenopausal Women Using Estradiol-Progestogen Therapy. *Obstet Gynecol*. 113(1):65-73. doi: 10.1097/AOG.0b013e31818e8cd6.

Section #14.a

(2020). Hormonal Management of Menopausal Symptoms in Women with a History of Gynecologic Malignancy. *Menopause: The Journal of The North American Menopause Society* Vol. 27. No. 2, pp.243-248 doi: 10.1097/GME.0000000000001447.

(2005). Menopausal Hormone Therapy (HT) in Patients with Breast Cancer. DOI: <https://doi.org/10.1016/j.maturitas.2005.03.004>.

(2001). A Prospective Study on Women with a History of Breast Cancer and with or without Estrogen Replacement Therapy. *Maturitas*, 39 (3), 217-25.

(2002). Estrogen Replacement Therapy in Patients with Early Breast Cancer. *Am J Obstet Gynecol.* 187(2):289-94.

Section #14.b

(2011). Breast Cancer in Postmenopausal Women After Hormone Therapy. *JAMA*, Vol 305, No. 5.

(2017). Estradiol Therapy and Breast Cancer Risk in Perimenopausal Women: A Systematic Review and Meta-Analysis. *Gynecol Endocrinol.* 33(2):87-92. doi: /10.1080/09513590.2016.1248932.

(2014). Progestogens in Postmenopausal Hormone Therapy and the Risk of Breast Cancer. *Maturitas* Vol 77, Issue 4, P. 311-317. doi: 10.1016/j.maturitas.2014.01.001.

(2013). Risk of Breast Cancer by Type of Menopausal Hormone Therapy: A Case-Control Study Among Post-Menopausal Women in France. *PLoS ONE* 8(11): e78016.doi:10.1371/journal.pone.0078016.

(2015). Progesterone or Progestin as Menopausal Ovarian Hormone Therapy: Recent Physiology-Based Clinical Evidence. *Curr Opin Endocrinol Diabetes Obes.* 22(6):495-501. doi: 10.1097/MED.0000000000000205.

(2013). HRT Optimization Using Transdermal Estradiol Plus Micronized Progesterone, A Safer HRT. *Climateric.* 16 Suppl 1:44-53. doi: 10.3109/13697137.2013.808563.

(2014). Do Statins Increase and Mediterranean Diet Decrease the Risk of Breast Cancer? *BMC Medicine.*

Section #15

(2015). Testosterone and Breast Cancer Prevention. *Maturitas.* 82(3):291-5. doi: 10.1016/j.maturitas2015.06.002.

(2019). Androgen Receptor is a Non-Canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers. *iScience*, 21, 341-358. doi: 10.1016/j.isci.2019.10.038.

(2004). Breast Cancer Incidents in Postmenopausal Women Using Testosterone in Addition to Usual Hormone Therapy. *Menopause*: September-October 2004 – volume 11 – Issue 5 – p 531-535 doi: 10.1097/01.GME.000011983.48235.D3.

(2013). Reduced Breast Cancer Incidence in Women Treated with Subcutaneous Testosterone, or Testosterone with Anastrozole: a Prospective, Observational Study. *Maturitas*. 76(4):342-9. doi: 10.1016/j.maturitas.2013.08.002.

(2019). Incidence of Invasive Breast Cancer in Women Treated with Testosterone Implants: a Prospective 10-year Cohort study. *BMC Cancer*, 30;19(1):1271. doi: 10.1186/s12885-019-6457-8.

Section 18

(2008). Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. *J Natl Cancer Inst*. 2008;100:1361-1367.

(2009). Hormone Replacement Therapy, Family History and Breast Cancer Risk Among Postmenopausal Women. *Epidemiology*, 20(5): 752-756. doi:10.1097/EDE.0b013e3181a71279.

(2017). Use of Hormone Replacement Therapy After Risk Reducing Salpingo-Oophorectomy and Risk of Malignancy in High Risk Genetic Mutation Carriers: A Pilot Study. *Gynecologic Oncology*. Volume 147, Issue 1 Page 223 doi:10.1016/j.ygyno.2017.07.087.

(2019). Hormone Replacement Therapy After Risk Reducing Salpingo-Oophorectomy in Patients with BRCA1 or BRCA2 mutations; A Systematic Review of Risks and Benefits. *Gynecologic Oncology*, Volume 153, Issue 1, Pages 192-200.

(2017). Use of Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy and Risk of Malignancy in High Risk Genetic Mutation Carriers: A Pilot Study. doi: 10.1016/j.ygyno.2017.07.087.

(2016). Use of Systemic Hormone Therapy in BRCA Mutation Carriers. *Menopause*. 23(8):1026-7. doi: 10.1097/GME0000000000000724.

(2012). BRCA Carriers, Prophylactic Salpingo-Oophorectomy and Menopause: Clinical Management Considerations and Recommendations. *Women's Health*, 8 (5), 543-555.

(2014). Hormone Therapy in Oophorectomized BRCA1/2 Mutation Carriers. *Menopause*. 21(7):763-768, doi: 10.1097/GME.000000000000126.

(2018). Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. *JAMA Oncology*. 4(8):1059-1065, doi: 10.1001/jamaoncol.2018.0211.

(2019). Risk-reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement therapy: If It Should Rain, Better a Drizzle than a Storm. *Medicina*, 55, 415; doi:10.3390/medicina55080415.

(2018). Hormone Replacement Therapy After Prophylactic Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Meta-Analysis. *Critical Review in Oncology/Hematology* Volume 132, Pages 111-115 doi: 10.1016/j.critrevonc.2018.09.018.

Section #19

(2003). Association of Estrone Levels with Estrogen Receptor-positive Breast Cancer Risk in Postmenopausal Japanese Women. *JAMA*.

(2017). The Presence of a Membrane-bound Progesterone Receptor Induces Growth of Breast Cancer with Norethisterone but not with Progesterone: A Xenograft Model. *Maturitas*, 102, 26-33.

(2016). Breast Cancer Patients Could Benefit From Controversial Hormone. <http://www.labmanager.com/news/2016/12/breast-cancer-patients-could-benefit-from-controversial-hormones>.

(2008). Could Transdermal Estradiol+Progesterone be a Safer Postmenopausal HRT? A Review. *Maturitas*, 60 (3), 185-201.

(2009). Estrogen-progestogen Menopausal Hormone Therapy and Breast Cancer: Does Delay from Menopause Onset to Treatment Initiation Influence Risks? *J Clin. Oncol*, (31) 5138-43.

(2015). Progesterone Receptor Modulates Era Action in Breast Cancer. *Nature* 523, 313-317.

(2009). Progestagen Component in Combined Hormone Replacement Therapy in Postmenopausal Women and Breast Cancer Risk: A Debated Clinical Issue. *Gynecol Endocrinol*, (12), 807-15.

(2015). Progesterone for Symptomatic Perimenopause Treatment Progesterone Politics, Physiology and Potential for Perimenopause. *OBGYN*, 3 (2), 109-120.

(2005). Progestins and Progesterone in Hormone Replacement Therapy and the Risk of Breast Cancer. doi/10.1016/j.jsbmb.2005.02.014.

(2012). Micronized Progesterone and its Impact on the Endometrium and Breast Vs. Progestogens. *Climacteric* 1, 18-25.

(2005). Breast Cancer Risk in Relation to Different Types of Hormone Replacement Therapy in the E3N-EPIC Cohort. *Int J. Cancer*, 114 (3), 448-454.

(2008). Unequal Risks for Breast Cancer Associated with Different Hormone Replacement Therapies: Results from the E3N Cohort Study. *Breast Cancer Res. Treat* 107 (1), 103-11.

(2013). Risk of Breast Cancer by type of Menopausal Hormone Therapy: A Case-control Study Among Post-Menopausal Women in France. *Plos One*, 8 (11), e78016.

(2005). Progesterone Inhibits Human Breast Cancer Cell Growth Through Transcriptional Upregulation of the Cyclin-dependent kinase inhibitor P27kip1 Gene. *Climacteric*, 579 (2), 5535-5541.

(2005). Progesterone Inhibits Human Breast Cancer Cell Growth Through Transcriptional Upregulation of the Cyclin-Dependent Kinase Inhibitor P27KIP1Gene. *Climacteric*, 579 (2), 5535-5541.

(2009). Progestogen Use in Women Approaching the Menopause and Breast Cancer Risk. *Maturitas* 62 (4), 338-342.

(2014). Is Breast Cancer Risk the Same for All Progestogens? *Arch Gynecol Obstet*, 290 (2), 207-209.

(2012). Percutaneous Estradiol/Oral Micronized Progesterone has less-adverse Effects and Different Gene Regulations than Oral Conjugated Equine Estrogens/Medroxyprogesterone Acetate in the Breast of Health Women in Vivo. *Gynecol Endocrinol*, 2, 12-15.

(2011). Effects of Percutaneous Estradiol-oral Progesterone Versus Oral Conjugated Equine Estrogens-medroxyprogesterone Acetate on Breast Cell Proliferation and BCL-2 Protein in Healthy Women. *Fertil Steril*, 95 (3), 1188-91.

(2010). Comparative Analysis of the Uterine and Mammary Gland Effects of Progesterone and Medroxyprogesterone Acetate. *Maturitas*, 65 (4), 386-391.

(1998). Estradiol and Progesterone Regulate the Proliferation of Human Breast Epithelial Cells. *Fertil Steril*, 69 (5), 963-969.

(2007). Effects of Estradiol with Micronized Progesterone or Medroxyprogesterone Acetate on Risk Markers for Breast Cancer in Postmenopausal Monkeys. *Breast Cancer Res Treat*, 101 (2), 125-134.